Enhanced Inhibition of Dipeptide Repeat Proteins for Neurodegenerative Disease Treatment

The present inventive concept relates to improved methods and compositions for treating neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), by enhancing the inhibition of dipeptide repeat proteins (DRPs) using Type I protein arginine methyltransferase (Type I PRMT) inhibitors.

The original patent disclosed the use of Type I PRMT inhibitors to decrease cellular toxicity caused by DRPs. However, the original patent has limitations, such as the lack of targeted delivery to motor neurons in the spinal column and brain, and the need for combination therapy to enhance therapeutic efficacy. The present inventive concept addresses these limitations by providing a system for targeted delivery, a method for treating neurodegenerative diseases in combination with neuroprotective agents, a pharmaceutical composition with C9ORF72-targeting RNA interference molecules, a method for monitoring DRP-induced toxicity, and a kit for combination therapy.

The present inventive concept comprises five key aspects: (1) a system for inhibiting DRPs, comprising a Type I PRMT inhibitor and a delivery agent for targeted delivery to motor neurons in the spinal column and brain; (2) a method for treating neurodegenerative diseases associated with DRPs, comprising administering a Type I PRMT inhibitor in combination with a neuroprotective agent to enhance therapeutic efficacy; (3) a pharmaceutical composition for treating ALS and FTD, comprising a Type I PRMT inhibitor and a C9ORF72-targeting RNA interference molecule to reduce DRP expression; (4) a method of monitoring DRP-induced toxicity in cells, comprising contacting the cells with a Type I PRMT inhibitor and detecting changes in cellular metabolism using a bioenergetic assay; and (5) a kit for treating neurodegenerative diseases associated with DRPs, comprising a Type I PRMT inhibitor, a neuroprotective agent, and instructions for use in combination therapy. These aspects work together to provide a comprehensive approach to treating neurodegenerative diseases, overcoming the limitations of the original patent.

The present inventive concept is novel and non-obvious over the original patent because it provides targeted delivery, combination therapy, and RNA interference molecules, which are not disclosed in the original patent. The inventive concept's combination of a Type I PRMT inhibitor with a neuroprotective agent and/or a C9ORF72-targeting RNA interference molecule provides a synergistic effect, enhancing therapeutic efficacy and reducing DRP expression.

Alternative embodiments of the inventive concept include using different types of delivery agents, such as nanoparticles or viral vectors, and different neuroprotective agents, such as antioxidants or anti-inflammatory compounds. Additionally, the pharmaceutical composition could be modified to include other therapeutic agents, such as RNA-based therapies or small molecule inhibitors.

The present inventive concept has significant commercial potential in the treatment of neurodegenerative diseases, particularly ALS and FTD. The market for ALS treatment is expected to grow significantly in the coming years, and the inventive concept's ability to provide a comprehensive approach to treating these diseases makes it an attractive option for pharmaceutical companies and investors.